- Mindray Bio-Medical’s fiscal year revenue came in at 36.73 billion yuan, falling short of the estimated 38.17 billion yuan.
- The company reported a net income of 11.67 billion yuan for the fiscal year.
- Analyst ratings show strong confidence in the company with 41 “buy” ratings, and no “hold” or “sell” ratings.
A look at Shenzhen Mindray Bio-Medical Electronics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 5 | |
| Growth | 4 | |
| Resilience | 5 | |
| Momentum | 2 | |
| OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Shenzhen Mindray Bio-Medical Electronics Co., Ltd., a company that manufactures and distributes medical equipment, has a promising long-term outlook based on Smartkarma Smart Scores. With a top-notch score of 5 in Dividend and Resilience, the company demonstrates strong potential for consistent payouts to investors and the ability to weather economic uncertainties. Moreover, scoring a 4 in Growth, Shenzhen Mindray Bio-Medical Electronics shows promising signs of expanding its operations over time. However, the company has room for improvement in Value and Momentum, scoring a 2 in both categories.
Overall, Shenzhen Mindray Bio-Medical Electronics is well-positioned in the medical equipment industry, with strengths in dividend payouts, resilience, and growth potential. Investors may find this company attractive for its stable performance and growth prospects, despite areas where improvements could be made to enhance value and momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
